News
DNLI
20.39
-0.39%
-0.08
Weekly Report: what happened at DNLI last week (0914-0918)?
Weekly Report · 5d ago
Denali Therapeutics (DNLI) Pulls Back As Pipeline Promise Keeps Fair Value In Focus
Simply Wall St · 09/16 15:23
Weekly Report: what happened at DNLI last week (0907-0911)?
Weekly Report · 09/14 09:15
Denali Therapeutics (DNLI) Stock Looks Stretched On Fair Value Yet Reasonable On Book Value
Simply Wall St · 09/12 10:18
Top Executive Makes Eye-Catching Move at Denali Therapeutics
TipRanks · 09/10 02:05
Is Denali Therapeutics (DNLI) Still Undervalued On Its Mixed Valuation Signals?
Simply Wall St · 09/08 21:32
Weekly Report: what happened at DNLI last week (0831-0904)?
Weekly Report · 09/07 09:14
Weekly Report: what happened at DNLI last week (0824-0828)?
Weekly Report · 08/31 09:16
Denali Therapeutics (DNLI) Stock Looks Rich On Book Value While Returns Stay Strong
Simply Wall St · 08/26 17:33
Denali Therapeutics Is Maintained at Buy by B. Riley Securities
Dow Jones · 08/25 17:57
Denali Therapeutics Price Target Raised to $35.00/Share From $30.00 by B. Riley Securities
Dow Jones · 08/25 17:57
B. Riley Securities Maintains Buy on Denali Therapeutics, Raises Price Target to $35
Benzinga · 08/25 17:47
Denali Therapeutics (DNLI) Stock Dropped, So Why Is It Drawing Fresh Attention?
Simply Wall St · 08/25 01:26
Weekly Report: what happened at DNLI last week (0817-0821)?
Weekly Report · 08/24 09:16
Denali’s DNL921 Trial: Early Alzheimer’s Safety Data That Could Shape Long-Term Upside
TipRanks · 08/20 16:32
Denali Therapeutics: Bullish On Avlayah And Their Prospects
Seeking Alpha · 08/19 12:01
Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy'
Seeking Alpha · 08/18 15:45
Denali Therapeutics (DNLI) Could Be 42% Undervalued Following Its Earnings Report
Simply Wall St · 08/17 16:27
Weekly Report: what happened at DNLI last week (0810-0814)?
Weekly Report · 08/17 09:16
Will AVLAYAH’s Launch And Cash Windfall Reshape Denali Therapeutics' (DNLI) Investment Narrative
Simply Wall St · 08/15 03:43
More
Webull provides a variety of real-time DNLI stock news. You can receive the latest news about Denali Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About DNLI
Denali Therapeutics Inc. is a biopharmaceutical company establishing a new class of biotherapeutics designed to cross the blood-brain barrier using its TransportVehicle platform. It is focused on building a portfolio of therapeutic candidates by investing in its TV franchises, i.e., Enzyme TV (ETV), Oligonucleotide TV (OTV), and Antibody TV (ATV), to advance programs for rare diseases, such as lysosomal storage diseases, and common diseases, such as Alzheimer's disease and Parkinson's disease. Its most advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (Hunter syndrome). TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for mucopolysaccharidosis IIIA (Sanfilippo syndrome type A), DNL593 (PTV:PGRN) for frontotemporal dementia-granulin, DNL628 (OTV:MAPT) for Alzheimer’s disease, and DNL952 (ETV:GAA) for Pompe disease. It is also pursuing opportunities in other disease areas including oncology.